10-Q: Nephros Reports Strong Q3 Growth, Returns to Profitability

Nephros, Inc. announced a significant financial turnaround, reporting net income and positive operating cash flow for the third quarter and first nine months of 2025, driven by robust revenue growth.

Summary

• Total net revenues increased by 35% to $4.76 million for the three months ended September 30, 2025, compared to $3.52 million in the prior year.
• For the nine months ended September 30, 2025, total net revenues grew by 37% to $14.06 million, up from $10.29 million in the same period of 2024.
• The company achieved a net income of $337,000 ($0.03 per diluted share) for Q3 2025, an 84% increase from $183,000 in Q3 2024.
• For the first nine months of 2025, Nephros reported a net income of $1.13 million ($0.10 per diluted share), a substantial improvement from a net loss of $275,000 in the corresponding 2024 period.
• Operating income for the nine months ended September 30, 2025, was $1.13 million, a significant turnaround from an operating loss of $311,000 in the prior year.
• Net cash provided by operating activities was $1.42 million for the nine months ended September 30, 2025, compared to net cash used of $1.80 million in the same period of 2024.
• Gross margin remained consistent at 61% for the three months ended September 30, 2025, and improved to 63% for the nine months, up from 61% in 2024.
• Selling, general and administrative expenses increased by 30% in Q3 and 15% for the nine months, primarily due to higher sales commissions and employee bonus accruals.
• Research and development expenses rose by 80% in Q3 and 44% for the nine months, driven by increased employee bonuses and salary expenses.
• The company maintains an accumulated deficit of $143.2 million as of September 30, 2025, but believes current cash balances are sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 8

Explanation: The company demonstrated a strong financial turnaround, moving from losses to profitability and generating positive operating cash flow. Revenue growth was robust across both quarterly and nine-month periods. While there are noted increases in operating expenses and an existing accumulated deficit, the overall trend is highly positive, indicating effective strategy execution and market acceptance. The identified material weakness in internal controls is being actively remediated and did not result in misstatements.

Positives

• Achieved significant financial turnaround, reporting net income of $337,000 in Q3 2025 and $1.13 million for the first nine months of 2025, compared to losses in the prior year periods.
• Generated positive net cash from operating activities of $1.42 million for the nine months ended September 30, 2025, a substantial improvement from negative cash flow in 2024.
• Experienced strong revenue growth, with total net revenues increasing by 35% in Q3 and 37% for the nine months, driven by higher programmatic revenue, new active sites, and significant growth in service revenue.
• Gross margin improved by 2 percentage points to 63% for the nine months ended September 30, 2025, due to reduced inventory reserve adjustments and a more favorable product mix.
• Successfully extended the License and Supply Agreement with Medica S.p.A. until December 31, 2028, securing continued access to proprietary ultrafiltration technology.
• Introduced a new water filtration solution validated for the reduction of Total PFAS, enhancing the product portfolio and addressing emerging contaminants.
• Management believes current cash balances are sufficient to fund operating plans through at least the next 12 months.

Negatives

• Selling, general and administrative expenses increased by 30% in Q3 and 15% for the nine months, outpacing revenue growth in Q3.
• Research and development expenses increased significantly by 80% in Q3 and 44% for the nine months, primarily due to higher employee bonuses and salaries.
• The company continues to carry a substantial accumulated deficit of $143.2 million as of September 30, 2025.
• Other expense, net, increased to $68,000 for the nine months ended September 30, 2025, primarily due to losses on foreign currency transactions.

Risks

• Significant challenges in obtaining market acceptance of products could adversely affect potential sales and revenues.
• Product-related deaths, serious injuries, or malfunctions could trigger recalls, class action lawsuits, and other events leading to expenses and negative publicity.
• Potential liability associated with the production, marketing, and sale of products, with defense expenses materially depleting assets and harming reputation.
• Risk of enforcement actions by the U.S. Food and Drug Administration (FDA) or other governmental agencies if products or marketing materials violate statutes or regulations.
• Inability to obtain funding when needed or on favorable terms to continue operations.
• Insufficient capital to successfully implement the business plan.
• Inability to effectively market products or sell water filtration products at competitive prices or profitably.
• Potential problems with suppliers, manufacturers, and distributors.
• Increased costs and/or disruptions in the supply chain due to the imposition of U.S. tariffs.
• Unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures.
• Inability to obtain appropriate or necessary regulatory approvals to achieve the business plan.
• Inability to secure or enforce adequate legal protection, including patent protection, for products.
• Inability to achieve sales growth in key geographic markets.
• Reliance on third-party contractors to install and service water filtration products, with any failure by these parties to perform adequately potentially harming business and reputation.

Future Outlook

Management anticipates that annual results will continue to be influenced by market acceptance of products, expense management, and the ability to achieve positive operating cash flow. The company believes its cash balances are sufficient to fund current operating plans for at least the next 12 months. There is an expectation that water safety management programs currently in medical facilities may migrate to commercial markets, creating future revenue opportunities, potentially surpassing current infection control revenue.

Management Comments

• We continue to focus on growth in sales and managing tight expenses in order to maintain profitability and positive cash flow from operations.
• Our operating plans are designed to help control operating costs and to increase revenue so we can continue to generate sufficient cash flows to fund operations.
• We believe that our VAR relationships have and will continue to facilitate growth in filter sales outside of the medical industry.
• We believe that the same water safety management programs currently underway at medical facilities may migrate to commercial markets.
• We believe that we have an opportunity to offer unique expertise and products to the commercial market, and that our future revenue from the commercial market could even surpass our infection control revenue.

Industry Context

Nephros operates in the critical water filtration market, serving both medical and commercial sectors. The medical segment benefits from increasing regulatory emphasis on waterborne pathogen control in healthcare settings, driven by bodies like CMS and The Joint Commission. The company's FDA 510(k)-cleared medical devices provide a competitive advantage. In the commercial sector, the company is expanding its offerings to address broader water quality concerns, including emerging contaminants like PFAS, aligning with growing public and regulatory awareness of safe drinking water. The company anticipates a trend where stringent water safety standards from medical environments will extend to commercial buildings, positioning it for future growth in that market.

Comparison to Industry Standards

• Nephros' medical-grade filters are FDA 510(k)-cleared as Class II medical devices, affirming their validated safety and performance in critical-use environments, a distinguishing feature.
• The company's dialysis ultrafilters assist in achieving hemodialysis-quality water that exceeds the ISO 23500-5 standard for ultrapure dialysate production.
• Nephros filters support compliance with CMS Conditions of Participation and The Joint Commission's water management expectations, which align with ANSI/ASHRAE Standard 188 and CDC guidance for hospitals and long-term care facilities.
• The company's newest solution for Total PFAS reduction expands its relevance in federally regulated facilities, where adherence to standards such as the Safe Drinking Water Act is a key consideration.
• Nephros anticipates that commercial buildings will increasingly need to follow basic requirements of ASHRAE-188, including water management plans, routine testing, and treatment plans, for which the company believes it is well-prepared with its expertise and solutions.

Management Changes

Corporate Governance

Related Party Transactions

• License and Supply Agreement with Medica S.p.A. for marketing and sale of filtration products, requiring minimum annual aggregate purchases (e.g., €4,629,000 for 2025).
• Non-exclusive distribution agreement with Donastar LLC for food service and hospitality sectors, which superseded a previous exclusive agreement.

Stakeholder Impact

• Shareholders: Positive financial results (net income, positive operating cash flow, revenue growth) are likely to be favorable. The increase in CEO compensation and formalization of director compensation could be viewed positively for management retention and motivation, but also as an increase in overhead. Remediation of internal control weakness enhances confidence in financial reporting.
• Employees: Higher accruals for employee bonuses and increased salary expenses indicate potential for improved compensation and morale.
• Customers: Continued product development, including PFAS reduction, and focus on medical-grade and commercial water solutions aim to provide enhanced water quality and safety, improving customer satisfaction and health outcomes.
• Suppliers/Distributors: The extended agreement with Medica S.p.A. ensures continued partnership. The shift of Donastar LLC to a non-exclusive distributor may open opportunities for other partners while maintaining the existing relationship.
• Creditors: Improved liquidity and profitability strengthen the company's financial position, potentially reducing credit risk.

Next Steps

• Continue to focus on growth in sales and managing tight expenses to maintain profitability and positive cash flow.
• Develop internal processes and controls, and provide additional training to the sales team, to properly capture relevant information for pricing contracts and remediate the material weakness in internal control over financial reporting.
• Evaluate opportunities to expand into new verticals where filtration technologies provide measurable value.
• Monitor and address potential risks related to market acceptance, product liability, regulatory compliance, funding, supply chain, and third-party contractor performance.

Key Dates

Recommendation

The company has demonstrated a significant financial turnaround, achieving net income and positive operating cash flow for the nine months ended September 30, 2025, compared to losses in the prior year. Revenue growth is robust at 37% year-over-year for the nine-month period, driven by strong programmatic sales and new active sites. While operating expenses have increased, the improved gross margin and overall profitability indicate effective operational leverage. The identified material weakness in internal controls is being actively addressed and did not lead to misstatements. The expansion into PFAS reduction and the strategic outlook for commercial market growth present compelling future opportunities. Given the strong positive momentum in core financial performance and strategic positioning, the stock presents an attractive 'buy' opportunity for growth-oriented investors.

Keywords

Water Filtration, Medical Devices, Infection Control, Dialysis, PFAS Reduction, Commercial Water Filters, Healthcare Facilities, Foodservice, Hospitality, SEC Filing, Quarterly Report, Financial Performance, Revenue Growth, Profitability